YOLFTbeta
Camurus AB

Camurus AB

CAMX · ST · Healthcare / Biotechnology

745.00SEK+6.00 (+0.81%)

Price History

Full chart

Market Stats

Previous Close739.00
Open739.50
Day Range732.50 – 745.00
52-Week Range430.80 – 710.00
Volume85.97K
Market Cap36.18B
P/E (TTM)55.27
Forward P/E27.03
EPS11.00
Dividend Yield0.00%
Beta0.51
50-Day Avg608.85
200-Day Avg570.32

About

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Fredrik Tiberg
  • Employees316
  • HeadquartersRydbergs torg 4, Lund, Sweden, 224 84, Sweden
  • Websitehttps://www.camurus.com

Leadership

  • Mr. Fredrik TibergPresident, CEO, CSO & Director · b. 1963
  • Mr. Anders Fink Vadsholt M.B.A., M.Sc.Chief Financial Officer · b. 1969
  • Ms. Susanne LagerlundVice President of Technical Operations · b. 1968
  • Mr. Rein Piir B.Sc.Vice President of Investor Relations · b. 1958
  • Bo A. C. TarrasWahlbergVP of Legal & Group General Counsel · b. 1975
  • Ms. Jane Buus Laursen Ph.D.Chief Corporate Development Officer · b. 1975
  • Ms. Maria LundqvistGlobal Head of Human Resources · b. 1966
  • Mr. Markus JohnssonSenior Vice President of R&D · b. 1972
  • Mr. Fredrik JoabssonChief Business Development Officer · b. 1972
  • Mr. Richard JamesonChief Commercial Officer · b. 1964

Financials

Income Statement

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue95.20M197.72M208.21M154.80M113.74M54.31M49.32M105.61M336.00M600.57M956.34M1.72B1.87B2.27B
Growth (%)-+107.68%+5.31%-25.65%-26.53%-52.25%-9.18%+114.12%+218.16%+78.74%+59.24%+79.52%+8.78%+21.30%
Cost of Revenue3.32M1.57M656.00K237.00K2.14M1.36M6.82M23.29M35.28M85.35M103.27M122.35M129.51M156.14M
Gross Profit91.88M196.14M207.55M154.56M111.60M52.95M42.50M82.32M300.71M515.22M853.08M1.59B1.74B2.11B
Gross Margin96.51%99.20%99.68%99.85%98.12%97.50%86.17%77.95%89.50%85.79%89.20%92.87%93.07%93.11%
Operating Expense73.12M68.83M145.23M358.67M214.05M296.48M329.72M442.40M507.28M627.58M781.12M1.06B1.27B1.23B
Operating Income18.76M127.32M62.32M-204.10M-102.45M-243.52M-287.22M-360.09M-206.57M-112.36M71.96M532.36M469.17M884.17M
Operating Margin19.71%64.39%29.93%-131.85%-90.08%-448.41%-582.34%-340.98%-61.48%-18.71%7.52%31.01%25.12%39.03%
EBITDA18.55M122.78M61.32M-200.72M-98.83M-239.28M-284.70M-353.05M-196.58M-97.72M87.59M562.54M568.24M909.18M
EBITDA Margin19.49%62.10%29.45%-129.66%-86.90%-440.60%-577.24%-334.31%-58.51%-16.27%9.16%32.77%30.43%40.13%
Net Income13.32M99.23M48.35M-159.54M-80.99M-190.57M-234.68M-289.87M-167.26M-90.45M55.55M431.44M428.39M735.57M
Net Income Margin13.99%50.19%23.22%-103.06%-71.21%-350.91%-475.81%-274.48%-49.78%-15.06%5.81%25.13%22.94%32.47%
R&D54.82M52.67M114.15M153.08M172.08M222.94M207.66M249.23M238.68M388.69M473.76M637.70M683.62M516.91M
R&D as % of Total Revenue57.58%26.64%54.82%98.89%151.29%410.51%421.05%236.00%71.04%64.72%49.54%37.14%36.60%22.82%
Interest Expense902.00K121.00K170.00K166.00K1.00M18.00K25.00K1.58M1.54M1.36M1.53M1.27M1.08M5.76M
Interest Expense % of Total Revenue0.95%0.06%0.08%0.11%0.88%0.03%0.05%1.50%0.46%0.23%0.16%0.07%0.06%0.25%

Balance Sheet

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets87.85M57.41M111.66M207.67M816.35M639.78M475.93M364.72M772.05M1.04B1.08B1.31B1.91B3.76B4.74B
Total Liabilities76.30M17.20M61.61M84.21M175.79M75.36M90.93M112.40M140.41M196.66M232.99M301.80M414.82M467.33M504.56M
Total Equity11.54M40.21M50.05M123.46M640.56M564.42M385.00M252.32M631.63M847.44M848.91M999.04M1.49B3.29B4.24B
Cash2.00K3.00K5.00K56.00K716.10M508.59M314.52M134.38M358.74M461.79M411.57M565.54M1.19B2.85B3.73B
Total Debt--------27.33M25.48M25.66M26.22M24.51M17.04M106.03M
Net Debt-2.00K-3.00K-5.00K-56.00K-716.10M-508.59M-314.52M-134.38M-331.41M-436.31M-385.92M-539.32M-1.17B-2.84B-3.62B

Cash Flow

Currency: SEK2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow24.73M163.06M69.43M-5.66M-207.79M-203.07M-274.08M-404.36M-238.83M-143.43M101.20M606.88M387.99M869.30M
Investing Cash Flow-42.16M-48.45M-94.44M156.97M-4.57M-2.14M-4.76M-25.90M-3.33M-4.94M5.38M-10.13M-29.37M-138.52M
Financing Cash Flow17.43M-114.62M25.06M564.72M4.85M11.14M99.85M654.29M347.85M98.90M43.70M28.76M1.30B158.30M
Capital Expenditure5.12M14.83M7.20M1.34M4.57M2.14M4.76M25.90M3.33M4.94M1.91M10.13M29.37M138.52M
Free Cash Flow19.62M148.23M62.23M-7.00M-212.35M-205.21M-278.85M-430.27M-242.16M-148.37M99.29M596.75M358.62M730.78M
FCF to OCF79.32%90.90%89.63%123.67%102.20%101.06%101.74%106.41%101.39%103.45%98.12%98.33%92.43%84.06%

Earnings

Report DateFeb 17, 2016May 17, 2016Jul 14, 2016Nov 8, 2016Feb 16, 2017May 3, 2017Jul 13, 2017Oct 26, 2017Feb 15, 2018May 3, 2018Jul 17, 2018Oct 25, 2018Feb 6, 2019May 9, 2019Jul 18, 2019Nov 8, 2019Feb 12, 2020May 7, 2020Jul 16, 2020Nov 5, 2020Feb 11, 2021May 6, 2021Jul 15, 2021Nov 4, 2021Feb 16, 2022May 12, 2022Jul 15, 2022Nov 10, 2022Feb 14, 2023May 10, 2023Jul 18, 2023Nov 9, 2023Feb 15, 2024May 8, 2024Jul 16, 2024Nov 7, 2024Feb 13, 2025May 15, 2025Jul 17, 2025Nov 6, 2025Feb 11, 2026May 11, 2026Jul 14, 2026Nov 5, 2026
EPS Estimate--------0.81-2.24-1.10-1.08-1.56-3.02-1.74-1.93-----0.83-0.41-0.97-0.15-0.34-0.11-0.26-0.010.070.310.453.850.590.961.121.411.641.992.783.113.812.833.343.254.36
EPS Actual-0.78-0.48-0.55-0.35-0.68-0.99-1.12-1.40-1.40-0.89-1.81-1.04-2.08-1.50-1.83-1.31-1.47-1.19-0.39-0.38-1.22-0.40-0.89-0.11-0.26-0.010.140.610.231.025.241.50-0.271.321.252.162.453.294.083.191.672.404.05-
Surprise--------72.84%37.50%19.09%-67.59%33.33%31.13%13.79%5.18%----54.22%-197.56%58.76%-493.33%67.65%-136.36%96.15%1500.00%771.43%-25.81%126.67%36.10%154.24%-128.13%17.86%-11.35%31.71%23.12%18.35%31.19%-16.27%-40.99%-28.14%24.62%-
TimingPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap36.18B
Enterprise Value33.20B
Trailing P/E55.27
Forward P/E27.03
PEG Ratio0.00
Price / Sales15.96
Price / Book7.94
EPS11.00
Book Value78.65
Revenue (TTM)2.27B
Gross Profit (TTM)2.11B
EBITDA822.98M
Profit Margin29.92%
Operating Margin41.66%
Return on Equity15.86%
Return on Assets10.47%
Shares Outstanding59.51M
Shares Float39.45M
Beta0.51
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Mar 6, 20191113:1019